Evidence map›Paper›PMID 35291214›Full record

ArticleJournal of clinical and translational science2022

Impact of the KL2/Catalyst Medical Research Investigator Training (CMeRIT) Program on the careers of early-stage clinical and translational investigators.

Miriam A Bredella, Kate M McGroarty, Lucy Kolessin, Linda F Bard, Anthony N Hollenberg, Seward B Rutkove

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miriam A BredellaHarvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5482-0440
Kate M McGroartyHarvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-5168-660X
Lucy KolessinHarvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts, USA.
Linda F BardHarvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts, USA.
Anthony N HollenbergDepartment of Medicine, Weill Cornell Medicine, New York, New York, USA.
Seward B RutkoveHarvard Catalyst, The Harvard Clinical and Translational Science Center, Harvard Medical School, Boston, Massachusetts, USA.

Funding

Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
NCATS NIH HHS KL2 TR002542
6 · The paper itself

Abstract

The Harvard Catalyst KL2/CMeRIT program is a 2-year mentored institutional career award that includes KL2 grants funded by National Institutes of Health (NIH) and CMeRIT grants funded by Harvard Catalyst nonfederal funds. The purpose of this study was to compare outcomes for early-stage investigators funded by the KL2/CMeRIT program to a group of applicants who were not chosen for support to assess the potential impact of the program on early career outcomes. Career data, including academic promotions, subsequent grant funding, and publication rates, from both successful and unsuccessful 2008-2018 KL2/CMeRIT applicants were compiled throughout the year 2020. Data were obtained directly through outreach to both groups and through assessment of online resources. The cohort comprised 487 individuals, 109 awardees, and 378 nonawardees. Awardees were more likely to be subsequently involved in clinical and translational research than nonawardees (92% vs 75%,

Indexed as

career development awardseducationKL2research trainingtranslational research

Identifiers

PMID35291214
PMCPMC8889229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.